Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer.
Gaylis FD, Emond B, Manceur AM, Tardif-Samson A, Morrison L, Pilon D, Lefebvre P, Ellis LA, Balaji H, Ireland A. Gaylis FD, et al. Among authors: manceur am. J Health Econ Outcomes Res. 2024 Oct 28;11(2):109-117. doi: 10.36469/001c.124208. eCollection 2024. J Health Econ Outcomes Res. 2024. PMID: 39479557 Free PMC article.
Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Shadman M, Salkar M, Srivastava B, Karve S, Emond B, Gogna P, Manceur AM, Lafeuille MH, Rava A, Sun H, Howarth A, Tomicki S, Agatep B, Jones B, Franceschini E, Saifan C, Bacchus S, Roeker L, Stephens DM. Shadman M, et al. Among authors: manceur am. Leuk Lymphoma. 2025 Jan;66(1):44-53. doi: 10.1080/10428194.2024.2402814. Epub 2024 Oct 1. Leuk Lymphoma. 2025. PMID: 39352001 Free article.
Economic and clinical burden of chronic corticosteroid use in patients with Crohn[apos]s disease initiated on biologic or conventional therapies in the US: A retrospective claims study.
Zhdanava M, Zhao R, Manceur AM, Ding Z, Boudreau J, Kachroo S, Kerner C, Izanec J, Pilon D. Zhdanava M, et al. Among authors: manceur am. J Am Pharm Assoc (2003). 2024 Mar-Apr;64(2):386-394.e10. doi: 10.1016/j.japh.2023.11.014. Epub 2023 Nov 11. J Am Pharm Assoc (2003). 2024. PMID: 37956768
Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis.
Sargent T, Tsang Y, Panjabi S, Funtanilla V, Germack HD, Gauthier-Loiselle M, Manceur AM, Cloutier M, Lefebvre P. Sargent T, et al. Among authors: manceur am. Adv Ther. 2023 Nov;40(11):5037-5054. doi: 10.1007/s12325-023-02658-z. Epub 2023 Sep 20. Adv Ther. 2023. PMID: 37728697 Free PMC article.
Treatment Patterns and Adverse Event-Related Hospitalization Among Patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-small Cell Lung Cancer After Treatment with EGFR Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy Regimens.
Marrett E, Kwong WJ, Xie J, Manceur AM, Sendhil SR, Wu E, Ionescu-Ittu R, Subramanian J. Marrett E, et al. Among authors: manceur am. Drugs Real World Outcomes. 2023 Dec;10(4):531-544. doi: 10.1007/s40801-023-00383-1. Epub 2023 Sep 2. Drugs Real World Outcomes. 2023. PMID: 37659039 Free PMC article.
32 results